产品
编 号：F001545
分子式：C13H18O2
分子量：206.28
分子式：C13H18O2
分子量：206.28
产品类型
规格
价格
是否有货
结构图
CAS No: 1002101-19-0
产品详情
生物活性：
Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. Fezagepras decreases renal, liver and pancreatic fibrosis. Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions.
体内研究：
Fezagepras (100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improvea glucose tolerance in type 2 diabetes eNOS-/-db/db mice.Animal Model:Type 2 diabetes eNOS-/-db/db mice
Dosage:100 mg/kg/day
Administration:Given via daily gavage from 8-20 weeks
Result:Compared with vehicle-treated mice, hyperglycemia was markedly decreased, and glucose tolerance was markedly improved.
体外研究：
Fezagepras (500 μM; 24 hours) inhibits TGF-β (10 ng/mL)-activated human hepatic stellate cells (HSCs) proliferation.Fezagepras (250 or 500 μM; 24hours) dose-dependently arrests HSCs at the G0/G1 phase without inducing apoptosis.
Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. Fezagepras decreases renal, liver and pancreatic fibrosis. Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions.
体内研究：
Fezagepras (100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improvea glucose tolerance in type 2 diabetes eNOS-/-db/db mice.Animal Model:Type 2 diabetes eNOS-/-db/db mice
Dosage:100 mg/kg/day
Administration:Given via daily gavage from 8-20 weeks
Result:Compared with vehicle-treated mice, hyperglycemia was markedly decreased, and glucose tolerance was markedly improved.
体外研究：
Fezagepras (500 μM; 24 hours) inhibits TGF-β (10 ng/mL)-activated human hepatic stellate cells (HSCs) proliferation.Fezagepras (250 or 500 μM; 24hours) dose-dependently arrests HSCs at the G0/G1 phase without inducing apoptosis.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备